Merck agreed to sell its consumer care unit to Germany's Bayer for $14.2 billion as part of efforts to focus on its branded prescription drug business. The acquisition, which is expected to be finalized in the second half of this year, will give Bayer rights to Merck's over-the-counter products, including allergy drug Claritin and Afrin nasal spray. The deal will also make Bayer the world's second-largest consumer health care firm. "This acquisition marks a major milestone on our path towards global leadership in the attractive non-prescription medicines business," Bayer CEO Marijn Dekkers said.

Related Summaries